The comparative clinical study evaluates the impact of HOPE on ex-situ split liver grafts used in pediatric recipients and benchmarks outcomes against static cold storage split grafts.
Bridge to Life raises $110 million through a Series C and debt package led by Soleus Capital. The financing supports scaling its VitaSmart hypothermic oxygenated perfusion technology.
Bridge to Life’s VitaSmart HOPE system preserves human uterus and intestine research grafts, according to data presented at the American Transplant Congress. The presentations report favorable metabolic markers in the grafts.
JAMA Surgery publishes the multicenter Bridge to HOPE trial, which reports that VitaSmart portal-venous HOPE improves preservation of high-risk livers. The report focuses on the system’s use in liver perfusion and preservation.
Duke University Hospital is the first U.S. center to preserve a donor liver using Bridge to Life’s VitaSmart system after FDA clearance. The case marks VitaSmart’s first commercial use in the United States; VitaSmart is a hypothermic oxygenated perfusion (HOPE) system.
